A03 - Role of glucosylceramides for Parkinson's Disease associated polyneuropathy and pain
Based on results of the previous funding period we now aim to identify mechanisms and therapeutic implications of glucosylceramide-driven sensory polyneuropathy and the risk of dementia in Parkinson's Disease (PD). We shall proceed with transitional studies in PD-patients and in PinkSNCA PD mice. Mechanistic studies shall be done in patient-derived primary cells and mouse primary neurons and encompass hypothesis-driven studies such as GlcCer effects of calcium channels, as well as omic-based screening techniques. Complex behavioral analyses and histology in mice shall reveal if and how glucosylceramides-reducing treatments prevent of attenuate polyneuropathy and/or dementia.
Prof. Dr. Irmgard Tegeder
Institute of Clinical Pharmacology
University Hospital Frankfurt
Theodor Stern Kai 7
60590 Frankfurt am Main